The occurrence of significant rebound redness and stinging after using Mirvaso is beginning to surface more and more in the public eye.
This recent letter to the editor in the Journal of the American Academy of Dermatology describes 3 cases of severe reaction to Mirvaso.
- Patient 1 had “in all areas where the medication had been applied and she had a severe skin burning sensation”,
- Patient 2 experienced “significant erythema, skin burning, and pruritus where BT was applied” and
- Patient 3 reported “erythema and burning in the areas of application” along with “progressively worsening rebound erythema and burning”.
The authors speculate that the real rate of adverse reactions to Mirvaso may be higher than that suggested by the Mirvaso Prescribing Information.
Letter to the Editor
Rebound erythema and burning sensation from a new topical brimonidine tartrate gel 0.33%
Journal of the American Academy of Dermatology, Volume 70, Issue 2 , Pages e37-e38, February 2014
Ethan T. Routt, BA, Jacob O. Levitt, MD
To the Editor: Brimonidine tartrate (BT) gel 0.33% (Mirvaso, Galderma Laboratories LP), an alpha-2 selective adrenergic receptor agonist and vasoconstrictor, reduces erythema of rosacea. The top 3 reported adverse events related to BT are erythema worse than baseline (4%), flushing (3%), and burning (2%). At least 1% of patients had an adverse reaction to the medication.
We report severe erythema in conjunction with burning sensation in 3 patients using BT. All reported reduced erythema 1 to 6 hours after application, followed by self-limited erythema, more severe than baseline, accompanied by burning over the next 12 hours and lasting roughly 12 hours. This phenomenon worsens with continued use. Urticaria and facial edema were absent. Even though the Mirvaso package insert reports infrequent erythema worse than baseline, this number may be higher in practice.
If you do have a bad reaction to Mirvaso be sure to report adverse reactions to Mirvaso to the FDA and Galderma